Key Points
- ANI Pharmaceuticals VP Meredith Cook sold 500 shares at an average price of $75.48, totaling $37,740, under a pre-arranged Rule 10b5-1 plan. She retained 74,424 shares worth approximately $5.62 million.
- ANI Pharmaceuticals reported quarterly EPS of $2.21, beating estimates by $0.17, while revenue rose 25.8% year over year to $266.04 million. The company issued fiscal 2026 EPS guidance of $9.19–$9.69.
- The stock opened at $74.77 and has a consensus analyst rating of “Moderate Buy”, with an average price target of $105.83; institutional investors own 76.05% of outstanding shares.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 500 shares of the business's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $75.48, for a total value of $37,740.00. Following the completion of the sale, the vice president directly owned 74,424 shares of the company's stock, valued at approximately $5,617,523.52. This trade represents a 0.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Meredith Cook also recently made the following trade(s):
- On Monday, July 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $81.84, for a total value of $40,920.00.
- On Friday, June 12th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $82.03, for a total value of $41,015.00.
ANI Pharmaceuticals Price Performance
ANIP opened at $74.77 on Friday. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The stock's 50 day simple moving average is $80.91 and its 200 day simple moving average is $79.05. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of 16.11 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 1 year low of $70.15 and a 1 year high of $99.50.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. The firm had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business's revenue was up 25.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, analysts predict that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.
Hedge Funds Weigh In On ANI Pharmaceuticals
Hedge funds and other institutional investors have recently made changes to their positions in the business. KBC Group NV purchased a new stake in ANI Pharmaceuticals in the first quarter worth $28,000. Advisors Asset Management Inc. bought a new stake in ANI Pharmaceuticals in the first quarter valued at $28,000. Hantz Financial Services Inc. increased its position in ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company's stock valued at $48,000 after purchasing an additional 249 shares during the period. Kemnay Advisory Services Inc. purchased a new position in ANI Pharmaceuticals during the 4th quarter valued at $48,000. Finally, State of Wyoming purchased a new position in ANI Pharmaceuticals during the 2nd quarter valued at $50,000. Institutional investors own 76.05% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on ANIP shares. Zacks Research lowered shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 14th. Guggenheim cut their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a report on Monday. Wall Street Zen cut shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Weiss Ratings cut shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday. Finally, Canaccord Genuity Group lowered their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a research note on Monday. Four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $105.83.
Check Out Our Latest Stock Analysis on ANIP
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
